1.85
price down icon5.13%   -0.10
after-market 시간 외 거래: 1.85
loading
전일 마감가:
$1.95
열려 있는:
$1.94
하루 거래량:
137.90K
Relative Volume:
1.09
시가총액:
$149.05M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5911
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
+10.78%
1개월 성능:
-9.76%
6개월 성능:
-43.77%
1년 성능:
+52.89%
1일 변동 폭
Value
$1.83
$1.9676
1주일 범위
Value
$1.56
$2.0353
52주 변동 폭
Value
$1.12
$4.20

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name
명칭
Inhibikase Therapeutics Inc
Name
전화
678-392-3419
Name
주소
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Name
직원
16
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
IKT's Discussions on Twitter

IKT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IKT
Inhibikase Therapeutics Inc
1.85 149.05M 0 -19.57M -17.24M -3.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-12 다운그레이드 H.C. Wainwright Buy → Neutral

Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스

pulisher
Jun 11, 2025

Squarepoint Ops LLC Acquires Shares of 28,411 Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Millennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

Jun 10, 2025
pulisher
Jun 03, 2025

Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

Jun 03, 2025
pulisher
May 27, 2025

Inhibikase Therapeutics Insider Buyers Pleased With US$788k Return On Investment - simplywall.st

May 27, 2025
pulisher
May 23, 2025

Inhibikase Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025
pulisher
May 17, 2025

13,129 Shares in Inhibikase Therapeutics, Inc. (NYSE:IKT) Purchased by Stifel Financial Corp - Defense World

May 17, 2025
pulisher
May 16, 2025

Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating - TipRanks

May 16, 2025
pulisher
May 14, 2025

Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Inhibikase Reports $93M War Chest, Accelerates Revolutionary PAH Treatment Development - Stock Titan

May 14, 2025
pulisher
May 12, 2025

Barclays PLC Purchases New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

May 12, 2025
pulisher
May 12, 2025

Former Inhibikase leader launches new biotech for midstage Parkinson's asset - Fierce Biotech

May 12, 2025
pulisher
May 05, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT) - PR Newswire

May 05, 2025
pulisher
May 02, 2025

Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH - Seeking Alpha

May 02, 2025
pulisher
May 01, 2025

Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World

May 01, 2025
pulisher
Apr 24, 2025

IKTInhibikase Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 24, 2025
pulisher
Apr 15, 2025

In wake of Anthos buyout, CFO McIntyre joins Inhibikase - biocentury.com

Apr 15, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Advances PAH Treatment with New Leadership - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints new CFO By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Names David McIntyre as CFO - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Announces Appointment Of David Mcintyre As CFO - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics appoints new CFO - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Strategic Hire: Venture Capital Veteran and Life Sciences CFO Expert Takes Helm at Inhibikase - Stock Titan

Apr 14, 2025
pulisher
Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025
pulisher
Apr 04, 2025

In the wake of Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) latest US$29m market cap drop, hedge funds owners may be forced to take severe actions - simplywall.st

Apr 04, 2025
pulisher
Apr 04, 2025

Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses - Yahoo

Apr 04, 2025
pulisher
Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

H.C. Wainwright maintains Neutral on Inhibikase Therapeutics stock - Investing.com India

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Reaffirms “Neutral” Rating for Inhibikase Therapeutics (NYSE:IKT) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Inhibikase Therapeutics' (IKT) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat

Mar 29, 2025
pulisher
Mar 28, 2025

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - The Manila Times

Mar 28, 2025
pulisher
Mar 27, 2025

Inhibikase Therapeutics Inc. (IKT) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Inhibikase Secures Future: $110M Funding, FDA Green Light, and New Leadership Fuel Growth - Stock Titan

Mar 27, 2025
pulisher
Mar 23, 2025

INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025
pulisher
Mar 21, 2025

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 05, 2025

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Zacks Investment Research

Mar 05, 2025
pulisher
Feb 25, 2025

After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury

Feb 25, 2025
pulisher
Feb 24, 2025

Inhibikase enhances leadership with new appointments By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics, Inc. Announces Management Appointments -February 24, 2025 at 08:00 am EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics Completes Merger with CorHepta Pharmaceuticals - TipRanks

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase enhances leadership with new appointments - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World

Feb 24, 2025
pulisher
Feb 18, 2025

Inhibikase Therapeutics Appoints Mark Iwicki as New CEO - TipRanks

Feb 18, 2025
pulisher
Feb 18, 2025

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire

Feb 18, 2025

Inhibikase Therapeutics Inc (IKT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Inhibikase Therapeutics Inc 주식 (IKT) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Kush Arvind
Director
Oct 21 '24
Buy
1.37
145,000
198,650
145,000
Munshi Amit
Director
Oct 21 '24
Buy
1.37
365,000
500,050
365,000
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):